For help on how to get the results you want, see our search tips.
4 results
Categories
Human Remove Human filter
Medicine
Referrals Remove Referrals filter
Referral PRAC recommendation
Revocation Remove Revocation filter
Risk minimisation measures Remove Risk minimisation measures filter
No further action Remove No further action filter
Referral status
CMDh final position Remove CMDh final position filter
European Commission final decision Remove European Commission final decision filter
Opinion provided by Committee for Medicinal Products for Human Use Remove Opinion provided by Committee for Medicinal Products for Human Use filter
Referral authorisation model
Nationally authorised product(s) Remove Nationally authorised product(s) filter
Centrally authorised product(s) Remove Centrally authorised product(s) filter
Referral type
Article 20 procedures Remove Article 20 procedures filter
Article 31 referrals Remove Article 31 referrals filter
Referral safety status
Yes Remove Yes filter
-
List item
Referral: Ifosfamide solutions
ifosfamide, associated names: Ifosfamide Eg, Ifo-Cell, Ifo-Cell N, Ifo-Cell N 2000, Article 31 referrals
Status: European Commission final decision, opinion/position date: 21/04/2021, EC decision date: 21/06/2021, Last updated: 19/07/2021 -
List item
Referral: Estradiol-containing (0.01% w/w) medicinal products for topical use
estradiol, associated names: Linoladiol, Linoladiol N, Linoladiol Estradiol, Estradiol Wolff, Montadiol, Article 31 referrals
Status: CMDh final position, opinion/position date: 30/01/2020, Last updated: 08/04/2020 -
List item
Referral: Xeljanz
tofacitinib, associated names: Xeljanz, Article 20 procedures
Status: European Commission final decision, opinion/position date: 14/11/2019, EC decision date: 31/01/2020, Last updated: 06/03/2020 -
List item
Referral: Lemtrada
alemtuzumab, associated names: Lemtrada, Article 20 procedures
Status: European Commission final decision, opinion/position date: 14/11/2019, EC decision date: 16/01/2020, Last updated: 04/02/2020